Dr. Rex Watkins is an associate at Wilson Sonsini Goodrich & Rosati, where his practice focuses on patent procurement—both domestic and international—for life sciences, physical science, medical device, and mechanical apparatus clients. In addition to patent drafting and prosecution, Rex has experience with freedom-to-operate analyses, validity and infringement opinions, IP due diligence, patent litigation, and licensing.
Rex has extensive technical expertise in the life sciences industry, including protein chemistry; enzymology; protein expression and purification; genetics; fluorescence; small molecule, peptide, and protein drugs; drug delivery; antisense nucleic acids; microarrays; RNA technologies; chemical synthesis; polymer chemistry; and organometallic catalysts. He also has significant patent prosecution experience with medical devices, including vascular access technologies, stents, inflation systems, and embolics.
Prior to joining the firm, Rex was a judicial extern for Judge Randall R. Radar of the U.S. Court of Appeals for the Federal Circuit. He also has experience as a research assistant at Utah State University and as an intern at a small biotechnology company.
Rex is practicing virtually in Utah, where he is licensed.
Dr. Rex Watkins is an associate at Wilson Sonsini Goodrich & Rosati, where his practice focuses on patent procurement—both domestic and international—for life sciences, physical science, medical device, and mechanical apparatus clients. In addition to patent drafting and prosecution, Rex has experience with freedom-to-operate analyses, validity and infringement opinions, IP due diligence, patent litigation, and licensing.
Rex has extensive technical expertise in the life sciences industry, including protein chemistry; enzymology; protein expression and purification; genetics; fluorescence; small molecule, peptide, and protein drugs; drug delivery; antisense nucleic acids; microarrays; RNA technologies; chemical synthesis; polymer chemistry; and organometallic catalysts. He also has significant patent prosecution experience with medical devices, including vascular access technologies, stents, inflation systems, and embolics.
Prior to joining the firm, Rex was a judicial extern for Judge Randall R. Radar of the U.S. Court of Appeals for the Federal Circuit. He also has experience as a research assistant at Utah State University and as an intern at a small biotechnology company.
Rex is practicing virtually in Utah, where he is licensed.
- J.D., J. Reuben Clark Law School, Brigham Young University, 2013Magna Cum Laude; Senior Editor, BYU Law Review
- Ph.D., Biochemistry, University of Wisconsin-Madison, 2010NSF Graduate Research Fellow
- B.S., Chemistry, Utah State University, 2005Summa Cum Laude
- Committee Member and Giles Rich Moot Court Competition Liaison, Intellectual Property Section, Utah State Bar, 2015-2016
- Subcommittee Chair, Utah Innovation Awards, Biotechnology and Medical Devices, 2014-2016
- Member, American Chemical Society, 2004-2016
- State Bar of California
- State Bar of Utah
- U.S. Patent and Trademark Office
- J.D., J. Reuben Clark Law School, Brigham Young University, 2013Magna Cum Laude; Senior Editor, BYU Law Review
- Ph.D., Biochemistry, University of Wisconsin-Madison, 2010NSF Graduate Research Fellow
- B.S., Chemistry, Utah State University, 2005Summa Cum Laude
- Committee Member and Giles Rich Moot Court Competition Liaison, Intellectual Property Section, Utah State Bar, 2015-2016
- Subcommittee Chair, Utah Innovation Awards, Biotechnology and Medical Devices, 2014-2016
- Member, American Chemical Society, 2004-2016
- State Bar of California
- State Bar of Utah
- U.S. Patent and Trademark Office
Select Publications
- Co-author with V. Norviel, L. Lieto, D. Hoffmeister, G. Ravitz, J. Ravitz, and C. Andres, "Citizen Petitions are Crucial in Managing A Drug’s Life Cycle," Law360, November 8, 2019
- Co-author, "Ribonuclease S redux," 47(3) Chemical Communications 973-5, 2011
- Co-author, "Fluorogenic affinity label for the facile, rapid imaging of proteins in live cells," 7(19) Organic & Biomolecular Chemistry 3969-75, 2009
- Co-author, "Divalent metal complexes of an amide-appended N3O-donor ligand: Synthesis, structural and spectroscopic features, and amide methanolyisis reactivity," 61(1) Journal of Coordination Chemistry 61-77, 2008
- Co-author, "Amide hydrolysis reactivity of a N4O-ligated zinc complex: Comparison of kinetic and thermodynamic parameters with those of the corresponding amide methanolysis reaction," 46(7) Inorganic Chemistry 2353-5, 2006
- Co-author, "Synthesis and characterization of a series of N3O-ligated mononuclear Mn(II) halide complexes," 359(4) Inorganica Chimica Acta 1282-90, 2006
- Co-author, "Manganese (II) chemistry of a new N3O-donor chelate ligand: Synthesis, X-ray structures, and magnetic properties of solvent- and oxalate-bound complexes," 11 Dalton Transactions 1891-6, 2005
- Co-author, "Mononuclear nitrogen/sulfur-ligated cobalt(II) methoxide complexes: Structural, EPR, paramagnetic 1H NMR, and electrochemical investigations," 16 Dalton Transactions 2398-9, 2004
Select Publications
- Co-author with V. Norviel, L. Lieto, D. Hoffmeister, G. Ravitz, J. Ravitz, and C. Andres, "Citizen Petitions are Crucial in Managing A Drug’s Life Cycle," Law360, November 8, 2019
- Co-author, "Ribonuclease S redux," 47(3) Chemical Communications 973-5, 2011
- Co-author, "Fluorogenic affinity label for the facile, rapid imaging of proteins in live cells," 7(19) Organic & Biomolecular Chemistry 3969-75, 2009
- Co-author, "Divalent metal complexes of an amide-appended N3O-donor ligand: Synthesis, structural and spectroscopic features, and amide methanolyisis reactivity," 61(1) Journal of Coordination Chemistry 61-77, 2008
- Co-author, "Amide hydrolysis reactivity of a N4O-ligated zinc complex: Comparison of kinetic and thermodynamic parameters with those of the corresponding amide methanolysis reaction," 46(7) Inorganic Chemistry 2353-5, 2006
- Co-author, "Synthesis and characterization of a series of N3O-ligated mononuclear Mn(II) halide complexes," 359(4) Inorganica Chimica Acta 1282-90, 2006
- Co-author, "Manganese (II) chemistry of a new N3O-donor chelate ligand: Synthesis, X-ray structures, and magnetic properties of solvent- and oxalate-bound complexes," 11 Dalton Transactions 1891-6, 2005
- Co-author, "Mononuclear nitrogen/sulfur-ligated cobalt(II) methoxide complexes: Structural, EPR, paramagnetic 1H NMR, and electrochemical investigations," 16 Dalton Transactions 2398-9, 2004
Upon closing, Arcellx will receive a $200 million equity investment to purchase 3,242,542 shares of its common stock. Following this investment, Gilead's estimated ownership will be 13 percent. Arcellx will also receive an upfront non-dilutive cash payment of $85 million at closing and will be eligible for potential milestone payments, including the advancement of lymphoma and the license for ARC-SparX, as well as additional milestones, to offset prespecified development costs over a limited period of time. The transaction is expected to close around year-end 2023.
The Wilson Sonsini team advising Arcellx on the transaction includes:
- Privacy Policy
- Terms of Use
- Accessibility